This is a clinical-stage biopharmaceutical company. Currently, it is working to develop drugs for problems in the central nervous system (CNS), respiratory system and metabolic diseases. They have two main drugs in development: RP5063 (also known as brilaroxazine) and RP1208. Brilaroxazine is being tested for various mental health conditions like schizophrenia, bipolar disorder, major depressive disorder, ADHD, Alzheimer’s disease and psychosis related to Parkinson’s disease. It’s also being explored for respiratory issues like pulmonary arterial hypertension and idiopathic pulmonary fibrosis. RP1208 is a triple reuptake inhibitor (TRI).